Related Experiment Videos
[The HOPE Study. What does it contribute to general practice?]
Insights
The HOPE study found that ramipril, an ACE inhibitor, significantly reduced cardiovascular events like heart attacks and strokes in high-risk patients. These benefits, including cardio- and nephroprotection, were observed even without substantial blood pressure reduction.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- High cardiovascular risk necessitates effective preventative strategies.
- The Renin-Angiotensin System (RAS) plays a crucial role in cardiovascular regulation.
- Angiotensin-Converting Enzyme (ACE) inhibitors are a class of drugs targeting the RAS.
Purpose of the Study:
- To investigate if inhibiting the RAS with ramipril prevents cardiovascular events in high-risk individuals.
- To evaluate the efficacy of ramipril in reducing myocardial infarction, stroke, and cardiovascular death.
Main Methods:
- The Heart Outcomes Prevention Evaluation (HOPE) study was a double-blind, placebo-controlled trial.
- Participants were patients with high cardiovascular risk.
- The primary endpoint combined myocardial infarction, stroke, and cardiovascular death.
Main Results:
- Ramipril significantly reduced myocardial infarction rates (9.9% vs. 12.2%) and cardiovascular deaths (6.1% vs. 8.1%).
- Strokes (3.4% vs. 4.9%) and revascularizations (16.0% vs. 18.6%) were also significantly decreased.
- A notable increase in cough rate (5%) was observed with ramipril.
- Benefits were largely independent of blood pressure reduction and particularly pronounced in type 2 diabetics.
Conclusions:
- Ramipril effectively prevents major cardiovascular events in high-risk patients.
- Cardio- and nephroprotective effects are significant, especially for type 2 diabetics.
- Albuminuria is a marker for cardiovascular event risk.
Abstract:
The HOPE study investigated the hypothesis that inhibition of the RAS with the ACE inhibitor, ramipril, prevents cardiovascular events in patients with a high cardiovascular risk. The primary endpoint of the double-blind, placebo-controlled study was the combination of myocardial infarction, stroke and cardiovascular death. The result was a significant reduction in the number of myocardial infarctions (9.9 vs. 12.2%), cardiovascular deaths (6.1 vs. 8.1%), strokes (3.4 vs. 4.9%) and revascularizations (16.0 vs. 18.6%) under the ACE inhibitor. The cough rate was raised (by 5%). The cardio- and nephroprotective benefits of ramipril were largely independent of the reduction in blood pressure achieved by the ACE inhibitor. The effects of rampipril in terms of micro- and macrovascular complications benefitted in particular type 2 diabetics with additional cardiovascular risk factors, so that this group should not be denied ramipril. The level of albumin excretion in the urine is directly coupled with the rate of cardiovascular events.